Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens

Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens

Cervical cancer develops as a result of infection with high-risk human papillomavirus (HPV) through persistent expression of early proteins E6 and E7. Our group pioneered a recombinant viral vector system based on Semliki Forest virus (SFV) for vaccination against cervical cancer. The most striking...

Full description

Bibliographic Details
Main Authors: Stephanie van de Wall, Karl Ljungberg, Peng Peng Ip, Annemarie Boerma, Maria L. Knudsen, Hans W. Nijman, Peter Liljeström, Toos Daemen
Format: Article
Language:English
Published: Taylor & Francis Group 2018-10-01
Series:OncoImmunology
Subjects:
replicon
alphavirus vector
semliki forest virus
hpv
immunotherapy
cancer vaccine
dna vaccine
therapeutic vaccination
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1487913

Internet

http://dx.doi.org/10.1080/2162402X.2018.1487913

Similar Items